Professional Documents
Culture Documents
S. ll
117TH CONGRESS
2D SESSION
To reduce the price of insulin and provide for patient protections with respect
to the cost of insulin.
A BILL
To reduce the price of insulin and provide for patient
protections with respect to the cost of insulin.
2
Sec. 101. Certification of insulin products.
Sec. 102. Patient protections for people with diabetes.
Sec. 103. Requirements with respect to cost-sharing for certain insulin prod-
ucts.
Sec. 104. Safe harbor for absence of deductible for insulin.
Sec. 105. Administration.
Sec. 201. Appropriate cost-sharing for insulin products covered under Medicare
part D.
Sec. 202. Additional protections under Medicare part D.
Sec. 203. Administration.
3
1 ‘‘(1)(A)(i) the manufacturer of such insulin
2 submits to the Secretary a request for the maximum
3 list price for such insulin during the plan year pur-
4 suant to such certification, in accordance with para-
5 graph (1) or (2) of subsection (b);
6 ‘‘(ii) the Secretary responds to the request
7 under clause (i) with a list price for such insulin for
8 the applicable plan year, in accordance with sub-
9 section (b); and
10 ‘‘(iii) the manufacturer attests to the Secretary
11 that it will not exceed the list price provided by the
12 Secretary under clause (ii) for the applicable plan
13 year; or
14 ‘‘(B) it is an insulin that was certified for a
15 previous plan year under subparagraph (A), and the
16 manufacturer of such insulin submits, not later than
17 a date specified by the Secretary, a certification that
18 the manufacturer has not increased the list price for
19 any plan year since the initial certification of such
20 insulin by more than the rate by which the consumer
21 price index for all urban consumers (all items; U.S.
22 city average) increased since the initial certification
23 under subparagraph (A), and will not increase the
24 list price during the applicable plan year for such in-
25 sulin by more than the rate by which the consumer
TAM22C07 8MC Discussion draft S.L.C.
4
1 price index for all urban consumers (all items; U.S.
2 city average) increased since the initial certification;
3 and
4 ‘‘(2) the Secretary includes the insulin in the
5 list of certified insulin publicly posted under sub-
6 section (e).
7 ‘‘(b) LIST PRICE FOR INITIAL CERTIFICATION.—
8 ‘‘(1) IN GENERAL.—For plan years beginning
9 on or after January 1, 2024, in the case of an insu-
10 lin that was licensed under section 351 and mar-
11 keted on or before December 31, 2021, the insulin
12 may be certified under subsection (a)(1)(A) for a
13 plan year if the list price of such insulin for the ap-
14 plicable plan year is not greater than the weighted
15 average negotiated price for the same insulin under
16 part D of title XVIII of the Social Security Act net
17 of all manufacturer rebates received by prescription
18 drug plans or MA-PD plans or pharmacy benefit
19 managers on their behalf from manufacturers with
20 respect to plan year 2021.
21 ‘‘(2) SPECIAL RULE FOR CERTAIN INSULIN.—In
5
1 mitting information attesting that the average list
2 price of such insulin for the plan year will not be
3 greater than the weighted average negotiated price
4 under part D of title XVIII of the Social Security
5 Act (net of all manufacturer rebates received by pre-
6 scription drug plans or MA-PD plans or pharmacy
7 benefit managers on their behalf) in plan year 2021,
8 of, as applicable—
9 ‘‘(A) all rapid-acting insulin products;
10 ‘‘(B) all short-acting insulin products;
11 ‘‘(C) all intermediate-acting insulin prod-
12 ucts;
13 ‘‘(D) all long-acting insulin products; or
14 ‘‘(E) all pre-mixed insulin products (ex-
15 cluding any insulin product that is mixed with
16 any non-insulin product).
17 ‘‘(c) WEIGHTED AVERAGE.—For purposes of sub-
18 section (b), the following shall apply:
19 ‘‘(1) The weighted average negotiated price de-
20 scribed in subsection (b)(1) shall be increased annu-
21 ally in accordance with the consumer price index for
22 all urban consumers (all items; U.S. city average).
23 ‘‘(2) In calculating the weighted average nego-
24 tiated price for insulin under paragraphs (1) and (2)
25 of subsection (b), the Secretary shall—
TAM22C07 8MC Discussion draft S.L.C.
6
1 ‘‘(A) consider separately each insulin with
2 the same dosage form and strength; and
3 ‘‘(B) weight the average negotiated price
4 for such insulin by the number of enrollees in
5 each prescription drug plan and MA–PD plan
6 under part D of title XVIII of the Social Secu-
7 rity Act for the applicable year.
8 ‘‘(d) DECERTIFICATION.—The Secretary shall estab-
9 lish a process by which an insulin that is certified under
10 this section for a plan year is decertified for such plan
11 year if the list price for such insulin, at any point during
12 such plan year, increases above the rate that is allowable
13 under subsection (b).
14 ‘‘(e) PUBLIC POSTING.—
15 ‘‘(1) IN GENERAL.—Not later than April 15,
16 2023, and not later than January 15 of each year
17 thereafter, the Secretary shall post—
18 ‘‘(A) a list of insulin products that are cer-
19 tified under subsection (a) for the applicable
20 plan year; and
21 ‘‘(B) the weighted average negotiated price
22 under part D of title XVIII of the Social Secu-
23 rity Act, net of all manufacturer rebates re-
24 ceived by prescription drug plans or MA-PD
25 plans or pharmacy benefit managers on their
TAM22C07 8MC Discussion draft S.L.C.
7
1 behalf, in plan year 2021, of, as applicable,
2 with respect to certified insulins—
3 ‘‘(i) all rapid-acting insulin products;
4 ‘‘(ii) all short-acting insulin products;
5 ‘‘(iii) all intermediate-acting insulin
6 products;
7 ‘‘(iv) all long-acting insulin products;
8 or
9 ‘‘(v) all pre-mixed insulin products
10 (excluding any insulin product that is
11 mixed with any non-insulin product).
12 ‘‘(2) REVISIONS FOR DECERTIFICATION.—In
8
1 increases the list price of a certified insulin
2 above the maximum list price that applies
3 under subsection (a)(1) pursuant to the certifi-
4 cation, a civil penalty in the amount equal to
5 the difference between such maximum list price
6 for the insulin and the actual wholesale acquisi-
7 tion cost for such insulin, multiplied by the
8 number of units sold at a price above such max-
9 imum list price.
10 ‘‘(B) ADMINISTRATION.—The provisions of
11 subsections (c) (with the exception of the first
12 sentence of paragraph (1) of such subsection),
13 (d), (e), (g), (h), (k), and (l) of section 1128A
14 of the Social Security Act shall apply to a civil
15 penalty under this subparagraph in the same
16 manner as such provisions apply to a penalty,
17 assessment, or proceeding under subsection (a)
18 of such section.
19 ‘‘(C) DEPOSIT.—Amounts collected under
20 subparagraph (A) shall be deposited into the
21 Federal Hospital Insurance Trust Fund under
22 section 1817 of the Social Security Act.
23 ‘‘(g) DEFINITIONS.—In this section:
24 ‘‘(1) INSULIN.—The term ‘insulin’ means insu-
25 lin that is licensed under subsection (a) or (k) of
TAM22C07 8MC Discussion draft S.L.C.
9
1 section 351 and continues to be marketed pursuant
2 to such licensure.
3 ‘‘(2) LIST PRICE.—The term ‘list price’ has the
4 meaning given the term ‘wholesale acquisition cost’
5 in section 1847A(c)(6)(B) of the Social Security
6 Act.’’.
7 (b) CONFORMING AMENDMENTS FOR DISCLOSURE
8 OF INFORMATION.—(1) Section 1927(b)(3)(D) of the So-
9 cial Security Act (42 U.S.C. 1396r–8(b)(3)(D)) is amend-
10 ed—
11 (A) in clause (iv), by striking ‘‘and’’ at the end;
12 (B) in clause (v), by striking the period at the
13 end and inserting ‘‘; and’’; and
14 (C) by inserting after clause (v) the following
15 new clause:
16 ‘‘(i) as the Secretary determines nec-
17 essary to carry out section 2796 of the
18 Public Health Service Act.’’.
19 (2) Section 1860D–12(b)(3)(D)(i) of the Social Secu-
20 rity Act (42 U.S.C. 1395w–112(b)(3)(D)(i)) is amended
21 by inserting ‘‘, or carrying out section 2796 of the Public
22 Health Service Act’’ before the period at the end.
23 (3) Section 1860D–15(d)(2)(B) of the Social Secu-
24 rity Act (42 U.S.C. 1395w–115(d)(2)(B)) is amended by
TAM22C07 8MC Discussion draft S.L.C.
10
1 inserting ‘‘or section 2796 of the Public Health Service
2 Act’’ before the period at the end.
3 (4) Section 1860D–15(f)(2)(A)(i) of the Social Secu-
4 rity Act (42 U.S.C. 1395w–115(f)(2)(A)(i)) is amended
5 by inserting ‘‘or section 2796 of the Public Health Service
6 Act’’ after ‘‘this section’’.
7 SEC. 102. PATIENT PROTECTIONS FOR PEOPLE WITH DIA-
8 BETES.
13 DIABETES.
11
1 or coverage and covered by the plan or cov-
2 erage; or
3 ‘‘(B) a price concession with respect to any
4 other product that is tied in any way to the cov-
5 erage of such insulin;
6 ‘‘(2) such insulin shall be treated as a selected
7 insulin product for purposes of section 2799A–12;
8 and
9 ‘‘(3) a group health plan, or health insurance
10 issuer with respect to such coverage, shall not im-
11 pose any prior authorization or other medical man-
12 agement requirements, or other similar conditions on
13 such insulin, except as clinically justified for safety
14 reasons, to ensure reasonable quantity limits and as
15 specified by the Secretary.
16 ‘‘(b) DEFINITIONS.—In this section:
17 ‘‘(1) INSULIN.—The term ‘insulin’ means insu-
18 lin that is licensed under subsection (a) or (k) of
19 section 351 and continues to be marketed pursuant
20 to such licensure.
21 ‘‘(2) LIST PRICE.—The term ‘list price’ has the
22 meaning given the term ‘wholesale acquisition cost’
23 in section 1847A(c)(6)(B) of the Social Security Act.
24 ‘‘(3) PRICE CONCESSION.—The term ‘price con-
25 cession’ means any discount, rebate, fee, or any
TAM22C07 8MC Discussion draft S.L.C.
12
1 other direct or indirect subsidy or remuneration that
2 serves to reduce the cost of prescription drug costs
3 incurred by the group health plan or health insur-
4 ance coverage.’’.
5 (b) ERISA.—
6 (1) IN GENERAL.—Subpart B of part 7 of sub-
7 title B of title I of the Employee Retirement Income
8 Security Act of 1974 (29 U.S.C. 1185 et seq.) is
9 amended by adding at the end the following:
10 ‘‘SEC. 726. PATIENT PROTECTIONS FOR PEOPLE WITH DIA-
11 BETES.
13
1 or coverage and covered by the plan or cov-
2 erage; or
3 ‘‘(B) a price concession with respect to any
4 other product that is tied in any way to the cov-
5 erage of such insulin;
6 ‘‘(2) such insulin shall be treated as a selected
7 insulin product for purposes of section 727; and
8 ‘‘(3) a group health plan, or health insurance
9 issuer with respect to such coverage, shall not im-
10 pose any prior authorization or medical management
11 requirements, or other similar conditions on such in-
12 sulin, except as clinically justified for safety reasons,
13 to ensure reasonable quantity limits and as specified
14 by the Secretary.
15 ‘‘(b) DEFINITIONS.—In this section:
16 ‘‘(1) INSULIN.—The term ‘insulin’ means insu-
17 lin that is licensed under subsection (a) or (k) of
18 section 351 of the Public Health Service Act (42
19 U.S.C. 262) and continues to be marketed pursuant
20 to such licensure.
21 ‘‘(2) LIST PRICE.—The term ‘list price’ has the
22 meaning given the term ‘wholesale acquisition cost’
23 in section 1847A(c)(6)(B) of the Social Security Act
24 (42 U.S.C. 1395w–3(c)(6)(B)).
TAM22C07 8MC Discussion draft S.L.C.
14
1 ‘‘(3) PRICE CONCESSION.—The term ‘price con-
2 cession’ means any discount, rebate, fee, or any
3 other direct or indirect subsidy or remuneration that
4 serves to reduce the cost of prescription drug costs
5 incurred by the group health plan or health insur-
6 ance coverage.’’.
7 (2) CLERICAL AMENDMENT.—The table of con-
8 tents in section 1 of the Employee Retirement In-
9 come Security Act of 1974 (29 U.S.C. 1001 et seq.)
10 is amended by inserting after the item relating to
11 section 725 the following:
‘‘Sec. 726. Patient Protections for People with Diabetes.’’.
17 BETES.
15
1 plan does not, directly or indirectly, receive from a
2 manufacturer of such insulin—
3 ‘‘(A) a price concession with respect to
4 such insulin received by an enrollee in the plan
5 and covered by the plan; or
6 ‘‘(B) a price concession with respect to any
7 other product that is tied in any way to the cov-
8 erage of such insulin;
9 ‘‘(2) such insulin shall be treated as a selected
10 insulin product for purposes of section 9827; and
11 ‘‘(3) a group health plan shall not impose any
12 prior authorization or other medical management re-
13 quirements, or other similar conditions on such insu-
14 lin, except as clinically justified for safety reasons,
15 to ensure reasonable quantity limits and as specified
16 by the Secretary.
17 ‘‘(b) DEFINITIONS.—In this section:
18 ‘‘(1) INSULIN.—The term ‘insulin’ means insu-
19 lin that is licensed under subsection (a) or (k) of
20 section 351 of the Public Health Service Act (42
21 U.S.C. 262) and continues to be marketed pursuant
22 to such licensure.
23 ‘‘(2) LIST PRICE.—The term ‘list price’ has the
24 meaning given the term ‘wholesale acquisition cost’
TAM22C07 8MC Discussion draft S.L.C.
16
1 in section 1847(c)(6)(B) of the Social Security Act
2 (42 U.S.C. 1395w–3(c)(6)(B)).
3 ‘‘(3) PRICE CONCESSION.—The term ‘price con-
4 cession’ means any discount, rebate, fee, or any
5 other direct or indirect subsidy or remuneration that
6 serves to reduce the cost of prescription drug costs
7 incurred by the group health plan.’’.
8 (2) CLERICAL AMENDMENT.—The table of sec-
9 tions for subchapter B of chapter 100 of such Code
10 is amended by adding at the end the following new
11 item:
‘‘Sec. 9826. Patient Protections for People with Diabetes.’’.
17
1 ance coverage shall provide coverage of selected insulin
2 products, and with respect to such products, shall not—
3 ‘‘(1) apply any deductible; or
4 ‘‘(2) impose any cost-sharing requirements in
5 excess of the lesser of, per 30-day supply—
6 ‘‘(A) $35; or
7 ‘‘(B) the amount equal to 25 percent of
8 the negotiated price of the selected insulin prod-
9 uct net of all price concessions received by or on
10 behalf of the plan or coverage, including price
11 concessions received by or on behalf of third-
12 party entities providing services to the plan or
13 coverage, such as pharmacy benefit manage-
14 ment services or third party administrators.
15 ‘‘(b) DEFINITIONS.—In this section:
16 ‘‘(1) SELECTED INSULIN PRODUCTS.—
18
1 censed and marketed, as selected by the
2 group health plan or health insurance
3 issuer;
4 ‘‘(ii) notwithstanding clause (i), for
5 any plan year beginning on or after Janu-
6 ary 1, 2024, includes—
7 ‘‘(I) all insulins for which a cer-
8 tification under section 2796 is in ef-
9 fect; and
10 ‘‘(II) any insulin for which a cer-
11 tification under such section 2796 was
12 in effect during the plan year, but
13 which was decertified under sub-
14 section (e) of such section during the
15 plan year, but only with respect to in-
16 dividuals who were enrolled in the
17 plan or coverage before such decerti-
18 fication.
19 ‘‘(B) CLARIFICATIONS.—
20 ‘‘(i) CERTIFIED INSULIN.—Insulin de-
21 scribed in subparagraph (A)(ii) may be
22 used to meet the requirement of subpara-
23 graph (A)(i) for the dosage form and type
24 of such insulin.
TAM22C07 8MC Discussion draft S.L.C.
19
1 ‘‘(ii) PRE-MIXED INSULIN.—A pre-
2 mixed insulin product is an insulin product
3 for purposes of subparagraph (A)(i) only if
4 the product contains only insulin, and is
5 not mixed with any non-insulin product.
6 ‘‘(2) INSULIN.—The term ‘insulin’ means insu-
7 lin that is licensed under subsection (a) or (k) of
8 section 351 and continues to be marketed pursuant
9 to such licensure.
10 ‘‘(c) OUT-OF-NETWORK PROVIDERS.—Nothing in
11 this section requires a plan or issuer that has a network
12 of providers to provide benefits for selected insulin prod-
13 ucts described in this section that are delivered by an out-
14 of-network provider, or precludes a plan or issuer that has
15 a network of providers from imposing higher cost-sharing
16 than the levels specified in subsection (a) for selected insu-
17 lin products described in this section that are delivered
18 by an out-of-network provider.
19 ‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall
20 not be construed to require coverage of, or prevent a group
21 health plan or health insurance coverage from imposing
22 cost-sharing other than the levels specified in subsection
23 (a) on, insulin products that are not selected insulin prod-
24 ucts, to the extent that such coverage is not otherwise re-
TAM22C07 8MC Discussion draft S.L.C.
20
1 quired and such cost-sharing is otherwise permitted under
2 Federal and applicable State law.
3 ‘‘(e) APPLICATION OF COST-SHARING TOWARDS
4 DEDUCTIBLES AND OUT-OF-POCKET MAXIMUMS.—Any
5 cost-sharing payments made pursuant to subsection (a)(2)
6 shall be counted toward any deductible or out-of-pocket
7 maximum that applies under the plan or coverage.’’.
8 (b) NO EFFECT ON OTHER COST-SHARING.—Section
9 1302(d)(2) of the Patient Protection and Affordable Care
10 Act (42 U.S.C. 18022(d)(2)) is amended by adding at the
11 end the following new subparagraph:
12 ‘‘(D) SPECIAL RULE RELATING TO INSU-
21
1 Patient Protection and Affordable Care Act (42 U.S.C.
2 18022(e)) is amended by adding at the end the following:
3 ‘‘(4) COVERAGE OF CERTAIN INSULIN PROD-
4 UCTS.—
22
1 (d) ERISA.—
2 (1) IN GENERAL.—Subpart B of part 7 of sub-
3 title B of title I of the Employee Retirement Income
4 Security Act of 1974 (29 U.S.C. 1185 et seq.), as
5 amended by section 102(b), is further amended by
6 adding at the end the following:
7 ‘‘SEC. 727. REQUIREMENTS WITH RESPECT TO COST-SHAR-
23
1 ‘‘(b) DEFINITIONS.—In this section:
2 ‘‘(1) SELECTED INSULIN PRODUCTS.—
24
1 section (e) of such section during the
2 plan year, but only with respect to in-
3 dividuals who were enrolled in the
4 plan or coverage before such decerti-
5 fication.
6 ‘‘(B) CLARIFICATIONS.—
7 ‘‘(i) CERTIFIED INSULIN.—Insulin de-
8 scribed in subparagraph (A)(ii) may be
9 used to meet the requirement of subpara-
10 graph (A)(i) for the dosage form and type
11 of such insulin.
12 ‘‘(ii) PRE-MIXED INSULIN.—A pre-
13 mixed insulin product is an insulin product
14 for purposes of subparagraph (A)(i) only if
15 the product contains only insulin, and is
16 not mixed with any non-insulin product.
17 ‘‘(2) INSULIN.—The term ‘insulin’ means insu-
18 lin that is licensed under subsection (a) or (k) of
19 section 351 of the Public Health Service Act (42
20 U.S.C. 262) and continues to be marketed pursuant
21 to such licensure.
22 ‘‘(c) OUT-OF-NETWORK PROVIDERS.—Nothing in
23 this section requires a plan or issuer that has a network
24 of providers to provide benefits for selected insulin prod-
25 ucts described in this section that are delivered by an out-
TAM22C07 8MC Discussion draft S.L.C.
25
1 of-network provider, or precludes a plan or issuer that has
2 a network of providers from imposing higher cost-sharing
3 than the levels specified in subsection (a) for selected insu-
4 lin products described in this section that are delivered
5 by an out-of-network provider.
6 ‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall
7 not be construed to require coverage of, or prevent a group
8 health plan or health insurance coverage from imposing
9 cost-sharing other than the levels specified in subsection
10 (a) on, insulin products that are not selected insulin prod-
11 ucts, to the extent that such coverage is not otherwise re-
12 quired and such cost-sharing is otherwise permitted under
13 Federal and applicable State law.
14 ‘‘(e) APPLICATION OF COST-SHARING TOWARDS
15 DEDUCTIBLES AND OUT-OF-POCKET MAXIMUMS.—Any
16 cost-sharing payments made pursuant to subsection (a)(2)
17 shall be counted toward any deductible or out-of-pocket
18 maximum that applies under the plan or coverage.’’.
19 (2) CLERICAL AMENDMENT.—The table of con-
20 tents in section 1 of the Employee Retirement In-
21 come Security Act of 1974 (29 U.S.C. 1001 et seq.),
22 as amended by section 102(b)(2), is further amend-
23 ed by inserting after the item relating to section 726
24 the following:
‘‘Sec. 727. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’.
TAM22C07 8MC Discussion draft S.L.C.
26
1 (e) INTERNAL REVENUE CODE.—
2 (1) IN GENERAL.—Subchapter B of chapter
3 100 of the Internal Revenue Code of 1986, as
4 amended by section 102(c), is further amended by
5 adding at the end the following new section:
6 ‘‘SEC. 9827. REQUIREMENTS WITH RESPECT TO COST-SHAR-
27
1 ‘‘(A) IN GENERAL.—The term ‘selected in-
2 sulin products’—
3 ‘‘(i) means for any plan year begin-
4 ning on or after January 1, 2023, at least
5 one of each dosage form (such as vial, pen,
6 or inhaler dosage forms) of each different
7 type (such as rapid-acting, short-acting, in-
8 termediate-acting, long-acting, and pre-
9 mixed) of insulin, when such form is li-
10 censed and marketed, as selected by the
11 group health plan; and
12 ‘‘(ii) notwithstanding clause (i), for
13 any plan year beginning on or after Janu-
14 ary 1, 2024, includes—
15 ‘‘(I) all insulins for which a cer-
16 tification under section 2796 of the
17 Public Health Service Act is in effect;
18 and
19 ‘‘(II) any insulin for which a cer-
20 tification under such section 2796 was
21 in effect during the plan year, but
22 which was decertified under sub-
23 section (e) of such section during the
24 plan year, but only with respect to in-
TAM22C07 8MC Discussion draft S.L.C.
28
1 dividuals who were enrolled in the
2 plan before such decertification.
3 ‘‘(B) CLARIFICATIONS.—
4 ‘‘(i) CERTIFIED INSULIN.—Insulin de-
5 scribed in subparagraph (A)(ii) may be
6 used to meet the requirement of subpara-
7 graph (A)(i) for the dosage form and type
8 of such insulin.
9 ‘‘(ii) PRE-MIXED INSULIN.—A pre-
10 mixed insulin product is an insulin product
11 for purposes of subparagraph (A)(i) only if
12 the product contains only insulin, and is
13 not mixed with any non-insulin product.
14 ‘‘(2) INSULIN.—The term ‘insulin’ means insu-
15 lin that is licensed under subsection (a) or (k) of
16 section 351 of the Public Health Service Act (42
17 U.S.C. 262) and continues to be marketed pursuant
18 to such licensure.
19 ‘‘(c) OUT-OF-NETWORK PROVIDERS.—Nothing in
20 this section requires a plan that has a network of providers
21 to provide benefits for selected insulin products described
22 in this section that are delivered by an out-of-network pro-
23 vider, or precludes a plan that has a network of providers
24 from imposing higher cost-sharing than the levels specified
25 in subsection (a) for selected insulin products described
TAM22C07 8MC Discussion draft S.L.C.
29
1 in this section that are delivered by an out-of-network pro-
2 vider.
3 ‘‘(d) RULE OF CONSTRUCTION.—Subsection (a) shall
4 not be construed to require coverage of, or prevent a group
5 health plan from imposing cost-sharing other than the lev-
6 els specified in subsection (a) on, insulin products that are
7 not selected insulin products, to the extent that such cov-
8 erage is not otherwise required and such cost-sharing is
9 otherwise permitted under Federal and applicable State
10 law.
11 ‘‘(e) APPLICATION OF COST-SHARING TOWARDS
12 DEDUCTIBLES AND OUT-OF-POCKET MAXIMUMS.—Any
13 cost-sharing payments made pursuant to subsection (a)(2)
14 shall be counted toward any deductible or out-of-pocket
15 maximum that applies under the plan.’’.
16 (2) CLERICAL AMENDMENT.—The table of sec-
17 tions for subchapter B of chapter 100 of such Code,
18 as amended by section 102(c)(2), is further amended
19 by adding at the end the following new item:
‘‘Sec. 9827. Requirements with respect to cost-sharing for certain insulin prod-
ucts.’’.
21 FOR INSULIN.
30
1 ‘‘(G) SAFE HARBOR FOR ABSENCE OF DE-
31
7 PART D.
32
1 ‘‘paragraph (4)’’ and inserting ‘‘para-
2 graphs (4) and (8)’’;
3 (C) in paragraph (3)(A), in the matter
4 preceding clause (i), by striking ‘‘and (4)’’ and
5 inserting ‘‘(4), and (8)’’;
6 (D) in paragraph (4)(A)(i), in the matter
7 preceding subclause (I), by striking ‘‘The cov-
8 erage’’ and inserting ‘‘Subject to paragraph (8),
9 the coverage’’; and
10 (E) by adding at the end the following new
11 paragraph:
12 ‘‘(8) TREATMENT OF COST-SHARING FOR SE-
33
1 ‘‘(I) IN GENERAL.—The coverage
2 shall provide benefits for such selected
3 insulin products, regardless of wheth-
4 er an individual has reached the ini-
5 tial coverage limit under paragraph
6 (3) or the annual out-of-pocket
7 threshold under paragraph (4), with
8 cost-sharing for a month’s supply that
9 does not exceed the maximum cost-
10 sharing amount (as defined in sub-
11 clause (II)).
12 ‘‘(II) MAXIMUM COST-SHARING
34
1 insulin product under the
2 prescription drug plan or
3 MA–PD plan.
4 ‘‘(B) DEFINITIONS.—In this paragraph:
5 ‘‘(i) SELECTED INSULIN PRODUCTS.—
35
1 ‘‘(AA) all insulins for
2 which a certification under
3 section 2796 of the Public
4 Health Service Act is in ef-
5 fect; and
6 ‘‘(BB) any insulin for
7 which a certification under
8 such section 2796 was in ef-
9 fect during the plan year,
10 but which was decertified
11 under subsection (e) of such
12 section during the plan year,
13 but only with respect to in-
14 dividuals who were enrolled
15 in the plan or coverage be-
16 fore such decertification.
17 ‘‘(II) ONLY COVERED PART D
36
1 clause (I)(bb) may be used to
2 meet the requirement of sub-
3 clause (I)(aa) for the dosage
4 form of such insulin.
5 ‘‘(bb) PRE-MIXED INSU-
37
1 1395w–104(b)(3)) is amended by adding at the end the
2 following new subparagraph:
3 ‘‘(I) REQUIRED INCLUSION OF SELECTED
38
1 prescription drug plan or MA–PD plan in which
2 the individual is enrolled.’’; and
3 (B) in subparagraph (E), by inserting the
4 following before the period at the end: ‘‘or
5 under section 1860D–2(b)(8) in the case of a
6 selected insulin product (as defined in subpara-
7 graph (B) of such section)’’; and
8 (2) in paragraph (2)—
9 (A) in subparagraph (B), by striking ‘‘A
10 reduction’’ and inserting ‘‘Subject to section
11 1860D–2(b)(8), a reduction’’;
12 (B) in subparagraph (D), by adding at the
13 end the following new sentence: ‘‘For plan year
14 2023 and each subsequent plan year, the
15 amount of the coinsurance applicable under the
16 preceding sentence to a month’s supply of a se-
17 lected insulin product (as defined in section
18 1860D–2(b)(8)(B)) dispensed to the individual
19 may not exceed the applicable copayment or co-
20 insurance amount for the product under the
21 prescription drug plan or MA–PD plan in which
22 the individual is enrolled.’’; and
23 (C) in subparagraph (E), by adding at the
24 end the following new sentence: ‘‘For plan year
25 2023 and each subsequent plan year, the
TAM22C07 8MC Discussion draft S.L.C.
39
1 amount of the copayment or coinsurance appli-
2 cable under the preceding sentence to a month’s
3 supply of a selected insulin product (as defined
4 in section 1860D–2(b)(8)(B)) dispensed to the
5 individual may not exceed the applicable copay-
6 ment or coinsurance amount for the product
7 under the prescription drug plan or MA–PD
8 plan in which the individual is enrolled.’’.
9 SEC. 202. ADDITIONAL PROTECTIONS UNDER MEDICARE
10 PART D.
40
1 the prescription drug plan or MA–PD plan of-
2 fered by the sponsor or organization does not,
3 directly or indirectly, receive from a manufac-
4 turer of such insulin—
5 ‘‘(i) a price concession with respect to
6 such insulin received by an enrollee in the
7 plan; or
8 ‘‘(ii) a price concession with respect to
9 any other product that is tied in any way
10 to the coverage of such insulin; and
11 ‘‘(B) a PDP sponsor offering a prescrip-
12 tion drug plan or a Medicare Advantage organi-
13 zation offering an MA–PD plan shall not im-
14 pose any prior authorization or other utilization
15 management requirements on such insulin, ex-
16 cept as clinically justified for safety reasons, to
17 ensure reasonable quantity limits and as speci-
18 fied by the Secretary.
19 ‘‘(2) DEFINITION OF PRICE CONCESSION.—The
41
1 SEC. 203. ADMINISTRATION.